Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Moderate to severe psoriasis describes how much of your body is covered in red ... An oral drug approved to treat psoriatic arthritis and plaque psoriasis in adults. How it works: Apremilast ...

Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...

in treating plaque psoriasis (PsO). The randomised clinical trial focused on the adult and adolescent patients aged 12 and above, having a body surface area as low as 1% and with at least moderate ...

It may show up like plaque psoriasis, or it may cause a bright red ... Even first-graders can put on moisturizers, and older kids can take full control. Pick the right therapy.

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...